Guggenheim Reiterates Buy Rating on Tenax Therapeutics
Guggenheim maintains its buy rating on Tenax Therapeutics, setting a $40 target, a 209.36% upside from the current price.
Key Points
- Guggenheim reiterated its buy rating on Tenax Therapeutics, Inc. (TENX) with a target price of $40 as of June 22, 2026.
- Guggenheim's $40 price target implies 209.36% upside from Tenax Therapeutics, Inc.'s ($TENX) current $12.93 share price.
- Shares of NASDAQCM:TENX traded near $12.00 on Monday, with a 52-week range between $5.62 and $18.38.
- Insiders including CFO Thomas Staab II have been buying shares, with significant positions also opened by institutional investors like Price T Rowe Associates.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim reiterated its buy rating for Tenax Therapeutics, Inc. (NASDAQCM:TENX) on June 22, 2026, setting a price target of $40. Analyst Seamus Fernandez maintained the optimistic outlook for the biotechnology company, which focuses on novel cardiopulmonary therapies.
Other Institutional Activity in Tenax Therapeutics
Price T Rowe Associates Inc opened a new position in Tenax Therapeutics, acquiring 2,951,116 shares valued at about $47.19 million. Janus Henderson Group PLC increased its holdings by 1,648,808 shares to a total of 1,815,474 shares, worth approximately $29.07 million, marking a 989.3% increase. Venrock Adviser, LLC also initiated a stake with 1,675,262 shares valued at $26.79 million. Perceptive Advisors LLC expanded its position by 1,008,640 shares to 1,447,782 shares, valued at $23.15 million, a 229.7% increase. Ikarian Capital, LLC added 50,000 shares, bringing its total to 1,017,600 shares worth about $16.27 million, reflecting a 5.2% increase.
Tenax Therapeutics, Inc. Stock Up 507.0%
Shares of NASDAQCM:TENX traded near $12.00 on Monday. Tenax Therapeutics has a market cap of approximately $318.3 million. The stock's 52-week range is between $5.62 and $18.38, with a 50-day moving average of $12.47 and a 200-day moving average of $11.05. The company is not currently profitable, with a negative forward P/E ratio of -8.51. Tenax maintains a strong liquidity position with a current ratio of 14.52 and a quick ratio of 13.99.
$TENX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Tenax Therapeutics, Inc.
There has been notable insider buying activity at Tenax Therapeutics. On May 11, 2026, Chief Financial Officer Thomas Staab II purchased 450,000 shares. Earlier in the year, on January 30, 2026, Interim CFO Thomas McGauley bought 50,000 shares. Additionally, on January 9, 2026, insiders Declan Doogan and Michael Davidson each acquired 30,000 shares.
Analysts Set New Price Targets
On June 22, 2026, Guggenheim maintained its buy rating on Tenax Therapeutics with a $40 price target. On the same day, Chardan Capital initiated coverage with a buy rating and a $27 target. Earlier, Piper Sandler maintained a buy rating with a $50 target on June 12, 2026.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina. It focuses on developing novel therapies for cardiopulmonary diseases. The company is working on several treatments, including TNX-101, TNX-102, and TNX-103, which target pulmonary hypertension in heart failure patients. Tenax was founded in 1967 and is led by CEO Christopher T. Giordano.
Bottom Line
Guggenheim's reiterated buy rating and $40 target price reflect continued confidence in Tenax Therapeutics' potential. Investors follow analyst ratings closely, although these are based on past performance and expectations, not a guarantee of future results. As always, investors should consider multiple factors when evaluating a stock.
Get Tenax Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TENX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.